|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
AU2019338207B2
(en)
|
2018-09-10 |
2025-01-02 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
SMT202500028T1
(it)
|
2018-09-10 |
2025-03-12 |
Mirati Therapeutics Inc |
Terapie combinate
|
|
CA3112043A1
(en)
|
2018-09-10 |
2020-03-19 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
US12208099B2
(en)
|
2018-09-10 |
2025-01-28 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
US12377101B2
(en)
|
2018-12-05 |
2025-08-05 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
WO2020146613A1
(en)
|
2019-01-10 |
2020-07-16 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
CN114615981B
(zh)
|
2019-08-29 |
2024-04-12 |
米拉蒂治疗股份有限公司 |
Kras g12d抑制剂
|
|
CN114761012B
(zh)
|
2019-09-24 |
2025-03-21 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
PH12022551513A1
(en)
|
2019-12-20 |
2023-04-24 |
Mirati Therapeutics Inc |
Sos1 inhibitors
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
US12702658B2
(en)
|
2020-04-24 |
2026-08-11 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
|
|
US12655160B2
(en)
|
2020-08-04 |
2026-06-16 |
Mirati Therapeutics, Inc. |
KRAS G12D inhibitors
|
|
TWI829003B
(zh)
*
|
2020-08-12 |
2024-01-11 |
美商建南德克公司 |
喹唑啉化合物之合成
|
|
EP4210833A4
(en)
|
2020-09-11 |
2024-09-11 |
Mirati Therapeutics, Inc. |
CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
|
|
EP4216951B1
(en)
|
2020-09-22 |
2026-04-01 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
CN116323624B
(zh)
*
|
2020-09-30 |
2026-07-10 |
上海医药集团股份有限公司 |
一种喹唑啉类化合物及其应用
|
|
WO2022105859A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras g12d inhibitors
|
|
WO2022109487A1
(en)
|
2020-11-23 |
2022-05-27 |
Merck Sharp & Dohme Corp. |
Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
|
|
EP4262807A4
(en)
|
2020-12-15 |
2025-04-23 |
Mirati Therapeutics, Inc. |
Azachinazoline pan-KRAS inhibitors
|
|
WO2022133038A1
(en)
|
2020-12-16 |
2022-06-23 |
Mirati Therapeutics, Inc. |
Tetrahydropyridopyrimidine pan-kras inhibitors
|
|
JP2024505594A
(ja)
*
|
2021-02-09 |
2024-02-06 |
メッドシャイン ディスカバリー インコーポレイテッド |
ピリミジン芳香環化合物
|
|
MX2023008463A
(es)
*
|
2021-02-16 |
2023-12-07 |
Leidos Biomedical Res Inc |
Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras).
|
|
KR20230169967A
(ko)
*
|
2021-03-12 |
2023-12-18 |
브리스톨-마이어스 스큅 컴퍼니 |
Kras g12d 억제제
|
|
CN115260214A
(zh)
*
|
2021-04-29 |
2022-11-01 |
药雅科技(上海)有限公司 |
稠环类krasg12d突变蛋白抑制剂的制备及其应用
|
|
CN115160309B
(zh)
*
|
2021-04-07 |
2024-04-09 |
药雅科技(上海)有限公司 |
Krasg12c突变蛋白杂环类抑制剂的制备及其应用
|
|
CN115141215B
(zh)
*
|
2021-03-30 |
2023-09-15 |
上海德琪医药科技有限公司 |
Kras g12d蛋白抑制剂和其用途
|
|
CN117715915A
(zh)
*
|
2021-04-09 |
2024-03-15 |
杭州英创医药科技有限公司 |
作为kras g12d抑制剂的杂环化合物
|
|
WO2022221386A1
(en)
*
|
2021-04-14 |
2022-10-20 |
Erasca, Inc. |
Selective kras inhibitors
|
|
US20240239788A1
(en)
*
|
2021-04-16 |
2024-07-18 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras g12d mutant
|
|
WO2022232331A1
(en)
*
|
2021-04-29 |
2022-11-03 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
EP4329888A1
(en)
*
|
2021-04-29 |
2024-03-06 |
Amgen Inc. |
2-aminobenzothiazole compounds and methods of use thereof
|
|
EP4332105A4
(en)
*
|
2021-04-30 |
2025-05-28 |
Genfleet Therapeutics (Shanghai) Inc. |
PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE
|
|
IL308195A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors for cancer treatment
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
PE20240088A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CN115385938A
(zh)
*
|
2021-05-25 |
2022-11-25 |
江苏恒瑞医药股份有限公司 |
苯并嘧啶类化合物、其制备方法及其在医药上的应用
|
|
CN117500799A
(zh)
*
|
2021-06-09 |
2024-02-02 |
伊莱利利公司 |
作为kras g12d抑制剂的取代的稠合吖嗪
|
|
WO2022258974A1
(en)
*
|
2021-06-10 |
2022-12-15 |
Redx Pharma Plc |
Quinazoline derivatives useful as ras inhibitiors
|
|
CN115466272A
(zh)
*
|
2021-06-11 |
2022-12-13 |
博瑞生物医药(苏州)股份有限公司 |
一种嘧啶并杂环化合物,包含其的药物组合物及其用途
|
|
WO2022262686A1
(en)
*
|
2021-06-13 |
2022-12-22 |
Jingrui Biopharma Co., Ltd. |
Kras g12d inhibitors
|
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
CA3221811A1
(en)
*
|
2021-06-30 |
2023-01-05 |
Dana-Farber Cancer Institute, Inc. |
Small molecule inhibitors of kras g12d mutant
|
|
CA3227138A1
(en)
|
2021-07-23 |
2023-01-26 |
Theras, Inc. |
Compositions and methods for inhibition of ras
|
|
EP4378478A4
(en)
|
2021-07-27 |
2025-11-12 |
Toray Industries |
MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
|
|
WO2023039240A1
(en)
*
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
|
WO2023061294A1
(zh)
*
|
2021-10-13 |
2023-04-20 |
再鼎医药(上海)有限公司 |
含氮杂环类衍生物调节剂、其制备方法及应用
|
|
EP4417606A4
(en)
*
|
2021-10-15 |
2025-10-22 |
Sunshine Lake Pharma Co Ltd |
NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
|
|
WO2023072188A1
(zh)
*
|
2021-10-29 |
2023-05-04 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
WO2023103523A1
(zh)
*
|
2021-12-09 |
2023-06-15 |
苏州浦合医药科技有限公司 |
取代的双环杂芳基化合物作为kras g12d抑制剂
|
|
WO2023138583A1
(zh)
*
|
2022-01-21 |
2023-07-27 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
JP7629580B1
(ja)
*
|
2022-01-21 |
2025-02-13 |
ユーシノヴァ・ファーマシューティカルズ・リミテッド |
ベンゾピリミジン化合物及びその使用
|
|
IL314486A
(en)
*
|
2022-02-03 |
2024-09-01 |
Mirati Therapeutics Inc |
Quinazoline compounds inhibit PAN-KRAS
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
WO2023151621A1
(zh)
*
|
2022-02-11 |
2023-08-17 |
泰励生物科技(上海)有限公司 |
具有抗kras突变肿瘤活性的化合物
|
|
CN118715215A
(zh)
*
|
2022-02-16 |
2024-09-27 |
美国安进公司 |
作为突变kras蛋白抑制剂的喹唑啉化合物及其用途
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
JP2025510656A
(ja)
*
|
2022-03-24 |
2025-04-15 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
複素環式化合物、その組成物、及びそれらを用いた治療方法
|
|
CN114573438A
(zh)
*
|
2022-03-31 |
2022-06-03 |
上海应用技术大学 |
一种单氟氯/溴代丙酮类化合物及其制备方法
|
|
CN116891488B
(zh)
*
|
2022-04-11 |
2025-12-12 |
成都海博为药业有限公司 |
稠环化合物、包含其的药物组合物及应用
|
|
AU2023265688A1
(en)
|
2022-05-06 |
2024-10-17 |
PAQ Therapeutics Inc. |
Kras g12d proteolysis targeting chimeras
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
EP4536364A1
(en)
|
2022-06-10 |
2025-04-16 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
TW202400600A
(zh)
*
|
2022-06-16 |
2024-01-01 |
美商昂勝醫療科技股份有限公司 |
喹唑啉衍生物、其組成物及方法
|
|
WO2024008068A1
(en)
*
|
2022-07-04 |
2024-01-11 |
Jacobio Pharmaceuticals Co., Ltd. |
K-ras mutant protein inhibitors
|
|
WO2024019103A1
(ja)
|
2022-07-21 |
2024-01-25 |
アステラス製薬株式会社 |
G12d変異krasタンパクに作用する複素環化合物
|
|
CN120019052A
(zh)
*
|
2022-08-05 |
2025-05-16 |
瑟拉斯有限公司 |
用于抑制kras的组合物和方法
|
|
US20260035376A1
(en)
*
|
2022-08-05 |
2026-02-05 |
Theras, Inc. |
Compositions and methods for inhibition of ras
|
|
JPWO2024034591A1
(cg-RX-API-DMAC7.html)
|
2022-08-09 |
2024-02-15 |
|
|
|
KR20250048078A
(ko)
|
2022-08-11 |
2025-04-07 |
브리스톨-마이어스 스큅 컴퍼니 |
Kras 억제제
|
|
AU2023322690A1
(en)
*
|
2022-08-12 |
2025-03-20 |
Astellas Pharma Inc. |
Anti cancer combinations comprising chemotherapy
|
|
EP4568674A1
(en)
|
2022-08-12 |
2025-06-18 |
Astellas Pharma Inc. |
Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
|
|
WO2024061333A1
(zh)
*
|
2022-09-21 |
2024-03-28 |
甘李药业股份有限公司 |
一种kras突变蛋白抑制剂、及其制备方法和应用
|
|
KR20250075709A
(ko)
*
|
2022-09-30 |
2025-05-28 |
트라스베다 리미티드 |
항-kras 돌연변이 종양 활성을 갖는 화합물
|
|
CN117886833A
(zh)
*
|
2022-10-13 |
2024-04-16 |
广东东阳光药业股份有限公司 |
一种嘧啶并吡啶化合物、其药物组合物及其用途
|
|
CN117263959A
(zh)
*
|
2022-10-24 |
2023-12-22 |
药雅科技(上海)有限公司 |
芳香类kras突变蛋白抑制剂的制备及其应用
|
|
AU2023377064A1
(en)
|
2022-11-09 |
2025-05-22 |
Revolution Medicines, Inc. |
Compounds, complexes, and methods for their preparation and of their use
|
|
CN116554208A
(zh)
*
|
2022-12-02 |
2023-08-08 |
苏州浦合医药科技有限公司 |
取代的双环杂芳基化合物作为kras g12d抑制剂
|
|
WO2024158242A1
(ko)
*
|
2023-01-25 |
2024-08-02 |
주식회사 엔바이오스 |
Kras g12d 돌연변이 억제용 화합물 및 이를 유효성분으로 포함하는 암질환 예방 또는 치료용 조성물
|
|
EP4680609A1
(en)
|
2023-03-15 |
2026-01-21 |
Quanta Therapeutics, Inc. |
Kras modulators and uses thereof
|
|
CN121487738A
(zh)
|
2023-03-30 |
2026-02-06 |
锐新医药公司 |
诱导ras gtp水解的组合物和其用途
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
CN121487951A
(zh)
|
2023-04-07 |
2026-02-06 |
锐新医药公司 |
大环ras抑制剂
|
|
AU2024251341A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
EP4695261A1
(en)
|
2023-04-14 |
2026-02-18 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
AR133027A1
(es)
|
2023-06-22 |
2025-08-20 |
Astellas Pharma Inc |
Composición farmacéutica que comprende un compuesto de quinazolina
|
|
JP2026523985A
(ja)
*
|
2023-06-28 |
2026-07-16 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
ピリミドピリジン化合物、その医薬組成物及びその使用
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
AU2024337016A1
(en)
*
|
2023-09-08 |
2026-04-16 |
Tyligand Bioscience (Shanghai) Limited |
Ras inhibitor
|
|
KR20260087586A
(ko)
|
2023-10-03 |
2026-06-11 |
피에이큐 테라퓨틱스 인코포레이티드 |
Kras 단백질분해 표적화 키메라
|
|
TW202523324A
(zh)
*
|
2023-10-08 |
2025-06-16 |
大陸商成都海博為藥業有限公司 |
一種稠環化合物及應用
|
|
US20250114346A1
(en)
|
2023-10-09 |
2025-04-10 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
|
|
KR20260110993A
(ko)
|
2023-10-09 |
2026-07-14 |
인사이트 코포레이션 |
Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
|
|
KR20260084633A
(ko)
*
|
2023-10-10 |
2026-06-05 |
청두 하이퍼웨이 파마슈티컬스 컴퍼니 리미티드 |
축합 고리 화합물 및 kras 억제제로서의 응용
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2025085580A1
(en)
*
|
2023-10-17 |
2025-04-24 |
Windermere Therapeutics, Inc. |
Kras(g12d) inhibitors
|
|
KR20260096846A
(ko)
|
2023-10-20 |
2026-06-24 |
머크 샤프 앤드 돔 엘엘씨 |
Kras 단백질의 소분자 억제제
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
WO2026090333A1
(en)
|
2024-10-23 |
2026-04-30 |
Incyte Corporation |
Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
|
|
US20260137674A1
(en)
|
2024-10-23 |
2026-05-21 |
Incyte Corporation |
Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|